• At Johns Hopkins Aramco Health JHAH we started an ASP

  2025-01-16

  

  At Johns Hopkins Aramco Health (JHAH), we started an ASP in 2011 with an educational program of physicians and pharmacist. The program was enhanced mid-2012 with the following interventions: a re-designed antibiotic sensitivity report [2], intravenous to oral conversion program, vancomycin pharmacok

• Oncogenic Ras blocker Several studies have explored the

  2025-01-16

  

  Several studies have explored the relationship between dental implants and MRONJ development. López-Cedrún JL et al. [13] reported that BRONJ developed after implant treatment in nine patients who were taking bisphosphonates orally. The mean interval between the initiation of treatment and the onset

• br Antiangiogenic therapy in non small cell

  2025-01-16

  

  Antiangiogenic therapy in non-small cell lung cancer (NSCLC) Antiangiogenic targeted therapy is an area of active research in which numerous agents have been studied and have been shown to be effective for many tumor types including NSCLC. Angiogenesis is frequently upregulated in malignant solid

• We provide here direct evidences that AT receptors are

  2025-01-16

  

  We provide here direct evidences that AT1 receptors are active in ADSCs since Ang II induces intracellular Ca mobilization in these cells. Data obtained during the observation of Ca influxes led us to the search for the ADSCs subpopulation constantly expressing AT1 receptor. ADSCs are necessary for

• br Under normal physiological conditions the

  2025-01-16

  

  Under normal physiological conditions, the agonist binds to AT1R on the surface of the plasma membrane and activates the receptor, mediating downstream signaling. Then, activated AT1R is phosphorylated by protein kinase C (PKC) [13] or G protein coupled receptor kinases (GPKs, such as GRK2 [13], G

• Acute myeloid leukemia treatment Furthermore a recently publ

  2025-01-16

  

  Furthermore, a recently published network meta-analysis including 30 trials in patients with hypertension and diabetes demonstrated that ARBs have efficacy similar to that of ACEIs for all-cause and cardiovascular mortality (HR 0.95, 95% CI 0.73 to 1.30 and HR 1.23, 95% CI 0.64 to 2.78, respectively

• The RE compartment has been shown to be

  2025-01-16

  

  The RE compartment has been shown to be critical for supplying AMPAR during LTP (Hanley, 2010; Park et al., 2004), but whether they also supply AMPAR for synaptic scaling has been less clear (Gainey et al., 2015; Tan et al., 2015). Interestingly, although an increase in μ3A is necessary for scaling,

• Analyses of brain CSCs isolated

  2025-01-16

  

  Analyses of BGP-15 receptor CSCs isolated from 24 pediatric and six adult brain tumors detected ALDH levels proportional to tumor type and aggressiveness. ALDH-expressing cells (ALDH+) formed spheroids while ALDH1 pharmacological inhibition by a combination of DEAB and RA decreased significantly sp

• While HTPCs are not immune cells

  2025-01-16

  

  While HTPCs are not immune cells, they produce IL-6, MCP-1 and other immunologically relevant factors (Mayer et al., 2016). Our results demonstrated that epinephrine and phenylephrine increased the mRNA expression levels of COX-2, IL-6 and MCP-1 in HTPCs without affecting the mRNA expression level o

• The cellular mechanism underlying the CGS mediated inhibitio

  2025-01-16

  

  The cellular mechanism underlying the CGS12066-mediated inhibition of glutamate release from hippocampal nerve terminals through presynaptic 5-HT1B receptors remains to be elucidated. 5-HT1B receptors are coupled to PTX-sensitive G proteins (Gi or Go) that have been shown to inhibit AC activity as w

• In the vasculature it is known that

  2025-01-16

  

  In the vasculature, it is known that A2A and A2B adenosine receptors are stimulatory for adenylyl-cyclase, leading to cyclic-AMP (cAMP) production and vasodilation, while the A1 and A3 adenosine receptors are linked to the inhibitory Gi, suppressing adenylyl-cyclase and favoring contraction. However

• Targeting the BCR is the ideal

  2025-01-16

  

  Targeting the BCR is the ideal strategy to identify the antigen reactive B cells. However, there is concern that B cells could be activated when BCR are bound and cross-linked by antigens, a possibility that is obviously negative for the treatment of autoimmune disease. Proby et al. (2000) tried to

• br The MIR The MIR is defined

  2025-01-16

  

  The MIR The MIR is defined by the ability of a single rat mAb to muscle or electric organ AChRs, typically mAb 35, to block binding of half or more of autoantibodies in human MG or EAMG [44], [45], [46]. Antibodies to the MIR are pathologically significant because they exhibit all the major patho

• In the U S surveillance of ACEs has garnered traction

  2025-01-16

  

  In the U.S., surveillance of ACEs has garnered traction at the state level through administration of the ACE Optional Module in CDC’s Behavioral Risk Factor Surveillance System (BRFSS) (Centers for Disease Control & Prevention, 2003). Since 2009, select states have implemented the ACEs optional modu

• Adarotene Activated MAP kinases transform the stimulus

  2025-01-15

  

  Activated MAP kinases transform the stimulus into the pathophysiological responses by phosphorylating downstream substrates, including transcription factors, cytoskeletal proteins involved in mRNA translation (Li et al., 2015). Among the numerous effectors that intervene in the TNF-α action is an ac

14394 records 24/960 page Previous Next First page 上5页 2122232425 下5页 Last page